{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:07:47Z","timestamp":1779246467484,"version":"3.51.4"},"reference-count":58,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Treatment options for relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) are limited, with no standard of care; prognosis is poor, with 4- to 6-month median survival. Avadomide (CC-122) is a cereblon-modulating agent with immunomodulatory and direct antitumor activities. This phase 1 dose-expansion study assessed safety and clinical activity of avadomide monotherapy in patients with de novo R\/R DLBCL and transformed lymphoma. Additionally, a novel gene expression classifier, which identifies tumors with a high immune cell infiltration, was shown to enrich for response to avadomide in R\/R DLBCL. Ninety-seven patients with R\/R DLBCL, including 12 patients with transformed lymphoma, received 3 to 5 mg avadomide administered on continuous or intermittent schedules until unacceptable toxicity, disease progression, or withdrawal. Eighty-two patients (85%) experienced \u22651 grade 3\/4 treatment-emergent adverse events (AEs), most commonly neutropenia (51%), infections (24%), anemia (12%), and febrile neutropenia (10%). Discontinuations because of AEs occurred in 10% of patients. Introduction of an intermittent 5\/7-day schedule improved tolerability and reduced frequency and severity of neutropenia, febrile neutropenia, and infections. Among 84 patients with de novo R\/R DLBCL, overall response rate (ORR) was 29%, including 11% complete response (CR). Responses were cell-of-origin independent. Classifier-positive DLBCL patients (de novo) had an ORR of 44%, median progression-free survival (mPFS) of 6 months, and 16% CR vs an ORR of 19%, mPFS of 1.5 months, and 5% CR in classifier-negative patients (P = .0096). Avadomide is being evaluated in combination with other antilymphoma agents. This trial was registered at www.clinicaltrials.gov as #NCT01421524.<\/jats:p>","DOI":"10.1182\/blood.2019002395","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T15:02:20Z","timestamp":1579878140000},"page":"996-1007","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":72,"title":["Avadomide monotherapy in relapsed\/refractory DLBCL: safety, efficacy, and a predictive gene classifier"],"prefix":"10.1182","volume":"135","author":[{"given":"Cecilia","family":"Carpio","sequence":"first","affiliation":[{"name":"Department of Hematology, Vall d\u2019Hebron Institute of Oncology, University Hospital Vall d\u2019Hebron, Universitat Aut\u00f2noma of Barcelona, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reda","family":"Bouabdallah","sequence":"additional","affiliation":[{"name":"Institut Paoli-Calmettes, Marseille, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Toulouse, Toulouse, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan-Manuel","family":"Sancho","sequence":"additional","affiliation":[{"name":"Catalan Institute of Oncology (ICO)\u2013Josep Carreras Leukaemia Research Institute (IJC)\u2013Hospital Universitari Germans Trias i Pujol, Badalona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Lyon-Sud, Pierre-B\u00e9nite, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Cordoba","sequence":"additional","affiliation":[{"name":"Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori, Fondazione G. Pascale, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Napoli, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mecide","family":"Gharibo","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drew","family":"Rasco","sequence":"additional","affiliation":[{"name":"South Texas Accelerated Research Therapeutics LLC, San Antonio, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Panizo","sequence":"additional","affiliation":[{"name":"Clinica Universidad de Navarra, Pamplona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose A.","family":"Lopez-Martin","sequence":"additional","affiliation":[{"name":"12 de Octubre University Hospital & Research Institute, Grupo Espa\u00f1ol de Terapias Inmuno-Biol\u00f3gicas en C\u00e1ncer (G\u00c9TICA), Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Humanitas Clinical and Research Center\u2014IRCCS, Humanitas Cancer Center, Rozzano, Milan, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Salar","sequence":"additional","affiliation":[{"name":"Hospital del Mar, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9560-1092","authenticated-orcid":false,"given":"Silvia","family":"Damian","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS, Milan, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-1028","authenticated-orcid":false,"given":"Alejandro","family":"Martin","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Salamanca and Instituto de Investigaci\u00f3n Biomedica de Salamanca (IBSAL), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), Salamanca, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Verhoef","sequence":"additional","affiliation":[{"name":"UZ Gasthuisberg Leuven, Leuven, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Van den Neste","sequence":"additional","affiliation":[{"name":"Cliniques Universitaires Saint-Luc, Universit\u00e9 de Louvain, Brussels, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Wang","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, San Diego, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzana","family":"Couto","sequence":"additional","affiliation":[{"name":"Genmab Pharmaceuticals, Princeton, NJ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraya","family":"Carrancio","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, San Diego, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Weng","sequence":"additional","affiliation":[{"name":"Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuehai","family":"Wang","sequence":"additional","affiliation":[{"name":"Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wei","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Berkeley Heights, NJ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Hege","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, San Francisco, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew W. B.","family":"Trotter","sequence":"additional","affiliation":[{"name":"Celgene Institute for Translational Research Europe, A Bristol-Myers Squibb Company, Seville, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Risue\u00f1o","sequence":"additional","affiliation":[{"name":"Celgene Institute for Translational Research Europe, A Bristol-Myers Squibb Company, Seville, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonia J.","family":"Buchholz","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, San Francisco, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick R.","family":"Hagner","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Summit, NJ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5512-1625","authenticated-orcid":false,"given":"Anita K.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Summit, NJ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pourdehnad","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, San Francisco, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"10","key":"2021031712451968000_B1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","article-title":"Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin lymphoma classification project","volume":"101","author":"Perry","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"2021031712451968000_B2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"2021031712451968000_B3","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2021031712451968000_B4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","article-title":"Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review","volume":"14","author":"Camicia","year":"2015","journal-title":"Mol Cancer"},{"issue":"23","key":"2021031712451968000_B5","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"27","key":"2021031712451968000_B6","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"36","key":"2021031712451968000_B7","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"issue":"31","key":"2021031712451968000_B8","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021031712451968000_B9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/10428194.2016.1187274","article-title":"Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12&lt;sup\/&gt;","volume":"58","author":"Baetz","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2021031712451968000_B10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study","volume":"52","author":"Van Den Neste","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2021031712451968000_B11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2021031712451968000_B12","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood. 2018;131(5):587-588]","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2021031712451968000_B13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.14813","article-title":"Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy","volume":"179","author":"Farooq","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"2021031712451968000_B14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2021031712451968000_B15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2021031712451968000_B16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published correction appears in Nat Med. 2018;24(8):1290-1291]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"2021031712451968000_B17","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"6769","key":"2021031712451968000_B18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"25","key":"2021031712451968000_B19","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"20","key":"2021031712451968000_B20","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2021031712451968000_B21","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"issue":"26","key":"2021031712451968000_B22","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies","volume":"33","author":"Scott","year":"2015","journal-title":"J Clin Oncol"},{"issue":"31","key":"2021031712451968000_B23","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study","volume":"29","author":"Thieblemont","year":"2011","journal-title":"J Clin Oncol"},{"issue":"22","key":"2021031712451968000_B24","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","article-title":"Clinical impact of the cell-of-origin classification and the MYC\/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group","volume":"35","author":"Staiger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2021031712451968000_B25","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1080\/10428194.2017.1287364","article-title":"Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review","volume":"58","author":"Schmidt-Hansen","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"2021031712451968000_B26","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator\u2019s choice in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2021031712451968000_B27","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"12","key":"2021031712451968000_B28","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/annonc\/mdy450","article-title":"Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue","volume":"29","author":"Ciavarella","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"2021031712451968000_B29","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2021031712451968000_B30","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","article-title":"Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study","volume":"2","author":"Keane","year":"2015","journal-title":"Lancet Haematol"},{"issue":"4","key":"2021031712451968000_B31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ajh.23398","article-title":"CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy","volume":"88","author":"Keane","year":"2013","journal-title":"Am J Hematol"},{"issue":"8","key":"2021031712451968000_B32","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/ajh.24758","article-title":"Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma","volume":"92","author":"Binder","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"2021031712451968000_B33","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.1038\/bcj.2017.37","article-title":"Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma [Blood Cancer J. 2017;7(5):e561]","volume":"7","author":"Kusano","year":"2017","journal-title":"Blood Cancer J"},{"issue":"11","key":"2021031712451968000_B34","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/blood-2003-07-2365","article-title":"Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project","volume":"103","author":"Rimsza","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2021031712451968000_B35","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2796.2008.02032.x","article-title":"Inflammatory cells and immune microenvironment in malignant lymphoma","volume":"264","author":"de Jong","year":"2008","journal-title":"J Intern Med"},{"issue":"4","key":"2021031712451968000_B36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2141.2008.07037.x","article-title":"Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma","volume":"141","author":"Linderoth","year":"2008","journal-title":"Br J Haematol"},{"issue":"6","key":"2021031712451968000_B37","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2015-02-628669","article-title":"CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL","volume":"126","author":"Hagner","year":"2015","journal-title":"Blood"},{"issue":"5971","key":"2021031712451968000_B38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"9","key":"2021031712451968000_B39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"7","key":"2021031712451968000_B40","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1042\/BCJ20160762","article-title":"Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway","volume":"474","author":"Collins","year":"2017","journal-title":"Biochem J"},{"issue":"6","key":"2021031712451968000_B41","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"issue":"11","key":"2021031712451968000_B42","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide [published correction appears in Leukemia. 2012;26(11):2445]","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2021031712451968000_B43","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bjh.14866","article-title":"Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity","volume":"179","author":"Hagner","year":"2017","journal-title":"Br J Haematol"},{"issue":"21","key":"2021031712451968000_B44","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1182\/blood.V122.21.2905.2905","article-title":"A first in human dose escalation study of CC-122, a first-in-class Pleiotropic Pathway ModulatorTM (PPM) compound in subjects with relapsed or refractory solid tumors, multiple myeloma and non-Hodgkin\u2019s lymphoma","volume":"122","author":"Rasco","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2021031712451968000_B45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1078-0432.CCR-18-1203","article-title":"A first-in-human study of novel cereblon modulator avadomide (CC-122) in advanced malignancies","volume":"25","author":"Rasco","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2021031712451968000_B46","first-page":"1008","article-title":"Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent","volume":"135","author":"Risue\u00f1o","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2021031712451968000_B47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021031712451968000_B48","article-title":"CC-122 exhibits greater preclinical activity in mantle cell lymphoma than lenalidomide through a combination of direct cell-autonomous and increased antibody dependent cell-mediated cytotoxicity [abstract]","volume":"128","author":"Hagner","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2021031712451968000_B49","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4161\/onci.19545","article-title":"Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients","volume":"1","author":"Manuel","year":"2012","journal-title":"OncoImmunology"},{"issue":"1","key":"2021031712451968000_B50","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1038\/ncomms3680","article-title":"Using synthetic templates to design an unbiased multiplex PCR assay","volume":"4","author":"Carlson","year":"2013","journal-title":"Nat Commun"},{"issue":"43","key":"2021031712451968000_B51","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2021031712451968000_B52","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.15797","article-title":"Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma","volume":"185","author":"Chiu","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"2021031712451968000_B53","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"2021031712451968000_B54","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"issue":"4","key":"2021031712451968000_B55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"2021031712451968000_B56","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/bloodadvances.2017010348","article-title":"IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation","volume":"2","author":"Li","year":"2018","journal-title":"Blood Adv"},{"issue":"23","key":"2021031712451968000_B57","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1494.1494","article-title":"CC-122 dosing on a novel intermittent schedule mitigates neutropenia and maintains clinical activity in subjects with relapsed or refractory diffuse large B cell lymphoma [abstract]","volume":"126","author":"Carpio","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2021031712451968000_B58","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1158\/1078-0432.CCR-16-1576","article-title":"The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma","volume":"23","author":"Keane","year":"2017","journal-title":"Clin Cancer Res"}],"updated-by":[{"DOI":"10.1182\/blood.2021011546","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/13\/996\/1803176\/bloodbld2019002395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/13\/996\/1803176\/bloodbld2019002395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T12:45:58Z","timestamp":1615985158000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/13\/996\/440487\/Avadomide-monotherapy-in-relapsed-refractory-DLBCL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,26]]},"references-count":58,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,3,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019002395","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/blood.2021011546","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,26]]}}}